Henrietta Lacks never volunteered to become one of the most important people in modern medicine. In 1951, while she was being treated for cervical cancer at Johns Hopkins Hospital, cells were taken from her tumor without her knowledge or consent. Those cells became HeLa—the first human cell line that could be reproduced easily and continuously in laboratory conditions.
HeLa cells helped scientists study disease, test treatments, examine human genetics, and develop medical technologies. Yet for decades, the woman behind the cells was largely absent from the public story. Her family did not share in the control, recognition, or commercial value created around biological material that began with her body.
The patient behind the cell line
Henrietta Lacks was born in Virginia in 1920 and later lived near Baltimore with her husband and children. After experiencing serious symptoms, she sought care at Johns Hopkins, one of the few major hospitals in the region that treated Black patients during segregation.
Doctors diagnosed an aggressive cervical cancer. During treatment, tissue samples were collected and provided to a laboratory studying human cells. The Smithsonian states plainly that this occurred without her knowledge or consent. Lacks died on October 4, 1951, at age thirty-one.
Unlike most human cells then grown in laboratories, cells from her tumor survived and divided rapidly. Researchers named the line “HeLa” using letters from her first and last names. The cells could be shared, multiplied, frozen, and used repeatedly, making them a powerful research tool.
A vast medical contribution
HeLa cells became important to research involving the polio vaccine, cancer, chemotherapy, viruses, gene mapping, radiation, in-vitro fertilization, and many other fields. Their ability to reproduce consistently allowed experiments to be repeated across laboratories and countries.
The National Institutes of Health reviewed the scientific literature and identified more than 110,000 publications citing the use of HeLa cells between 1953 and 2018. That scale makes clear that this was not one isolated experiment. Henrietta Lacks’s cells became part of the infrastructure of biomedical science.
Scientific benefit, however, does not cancel the conditions under which the cells were obtained. Medical progress and ethical failure can exist in the same history. Understanding both is necessary to honor the contribution truthfully.
Consent and the unequal medical system
Standards and laws governing tissue research were different in 1951, and informed-consent rules developed substantially in later decades. Historical context explains institutional practice, but it does not remove the human question: a patient’s biological material was used for purposes she was never told about and never had the opportunity to accept or refuse.
Race and economic position shaped the setting. Lacks received care within a segregated medical system that offered Black patients fewer choices and less power. Her story is therefore connected to a broader history of Black communities encountering medical exploitation, unequal treatment, and exclusion from decision-making.
Modern federal protections include institutional review, informed-consent requirements, and ethical principles such as respect for persons, beneficence, and justice. But questions involving stored specimens, secondary research, genetic privacy, and commercialization remain complicated. The history of HeLa continues to influence those debates.
Privacy reaches beyond one person
Genomic information can reveal facts not only about the individual whose cells are studied but also about biological relatives. When researchers published HeLa genome information, the potential privacy effect extended to the Lacks family.
In 2013, the NIH worked with family members to establish the NIH–Lacks Family Agreement. It created controlled access to HeLa whole-genome sequence data, included family representatives in the review process, promoted acknowledgment of Henrietta Lacks, and sought greater transparency. The agreement did not rewrite what happened in 1951, but it established a more respectful role for the family in decisions involving genomic data.
Recognition is necessary—but not the entire question
Public memorials, portraits, educational programs, and institutional statements have increasingly restored Henrietta Lacks’s name to the story. Recognition matters because language such as “HeLa” once allowed science to discuss the cells while overlooking the person.
But recognition alone does not settle questions of ownership and benefit. Laboratories and companies have used HeLa cells in research and commercial activity for decades. That history asks who should control biological materials, whether donors or families should share in benefits, and how institutions should respond when valuable research originated without meaningful consent.
The answers are not simple. Unrestricted payment rules could create new inequalities or interfere with research, while ignoring profit can repeat a system in which institutions gain value from people who lack power. Ethical policy must protect scientific discovery without treating human beings as raw material.
Remembering the whole legacy
Henrietta Lacks should not be reduced to cells taken from her body. She was a woman, mother, wife, and member of a family whose lives were affected long after her death. Nor should the medical importance of HeLa be minimized. The contribution is extraordinary precisely because its human and scientific dimensions are both so large.
The legacy of Henrietta Lacks is not a choice between celebrating science and confronting injustice. It requires both: gratitude for discoveries that saved and improved lives, and a lasting commitment to consent, dignity, privacy, recognition, and fairness for the people who make discovery possible.
Sources and further reading
- Smithsonian NMAAHC — Henrietta Lacks (HeLa): The Mother of Modern Medicine
- National Institutes of Health — HeLa Cells: A Lasting Contribution
- National Institutes of Health — NIH–Lacks Family Agreement
- National Human Genome Research Institute — Human Subjects Research in Genomics
- U.S. Department of Health and Human Services — The Belmont Report